Main Article Content

Ambreen Afridi
Afsheen Mahmood
Munir Hussain


Heart Failure, Pediatric, Hemoglobin, Prognosis


Introduction: Despite the many challenges linked to pediatric heart failure, little is known about the predictive importance of hemoglobin levels in this group. To improve patient outcomes, our aim was to look into this relationship.

Objectives: To assess the relationship between hemoglobin levels and the severity of left ventricular dysfunction in pediatric heart failure, informing personalized therapeutic strategies.

Study design: A cross-sectional study.

Duration and Place of Study: Department of Community Medicine Khyber Girls Medical College, Peshawar, Between 05-Feb 2021 And 05-Feb 2022.

Methods: Our study of paediatric heart failure patients assessed haemoglobin levels as well as the degree of left ventricular dysfunction. at the Tartary Care Hospital in Peshawar.

Results: Higher levels of left ventricular dysfunction were linked to decreased haemoglobin levels in 684 people. There were 310 (45.3%) females and 374 (54.7%) males, almost evenly distributed by gender. The average age was 6.8 years. Haemoglobin levels averaged 11.7 g/dL (SD = 1.2) in mild cases, 11.4 g/dL (SD = 1.3) in intermediate cases, and 10.8 g/dL (SD = 1.4) in severe cases.

Conclusion: Haemoglobin levels in paediatric heart failure show potential as prognostic indicators, highlighting the need for more studies to create tailored medicines and improve outcomes.

Abstract 53 | Pdf Downloads 18


1. Rossano JW, Kim JJ, Decker JA, Price JF, Zafar F, Graves DE, Morales DL, Heinle JS, Bozkurt B, Towbin JA, Denfield SW, Dreyer WJ, Jefferies JL. Prevalence, morbidity, and mortality of heart failure–related hospitalizations in children in the United States: a population-based study. Journal of cardiac failure. 2012 Nov 1;18(11):459-70. DOI: 10.1016/j.cardfail.2012.05.008.
2. Mozos I, Borzak G, Caraba A, Mihaescu R. Arterial stiffness in hematologic malignancies. OncoTargets and therapy. 2017;10:1381. DOI: 10.2147/OTT.S123817.
3. Anand IS. Anemia and chronic heart failure implications and treatment options. Journal of the American College of Cardiology. 2008 Jan 15;52(5):501-11. DOI: 10.1016/j.jacc.2008.04.044.
4. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander?. Archives of internal medicine. 2003 Mar 24;163(6):1400-4. DOI: 10.1001/archinte.163.12.1400.
5. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008 Aug 19;118(20):2139-47. DOI: 10.1161/CIRCULATIONAHA.108.788684.
6. Ossa Galvis MM, Bhakta RT, Tarmahomed A, et al. Cyanotic Heart Disease. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500001/
7. Hoffman JI, Kaplan S. The incidence of congenital heart disease. Journal of the American College of Cardiology. 2002 Jun 5;39(12):1890-900. DOI: 10.1016/S0735-1097(02)01886-7.
8. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, Canter CE, Wilkinson JD, Lipshultz SE. Incidence, causes, and outcomes of dilated cardiomyopathy in children. Jama. 2006 Mar 8;296(15):1867-76.
DOI: 10.1001/jama.296.15.1867.
9. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138(1):80-98. doi:10.1161/CIRCULATIONAHA.118.030099
10. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017
11. Silverberg DS, Wexler D, Blum M, Iaina A, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Shapira I. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology. 2000 Feb 1;35(7):1737-44. DOI: 10.1016/s0735-1097(00)00587-5.
12. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. Journal of cardiac failure. 2011 Sep 1;17(9):899-906. DOI: 10.1016/j.cardfail.2011.06.414.
13. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010 May 4;121(17):245-51. DOI: 10.1161/CIRCULATIONAHA.109.881084.
14. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology. 2001 Apr 1;37(7):1775-80. DOI: 10.1016/s0735-1097(01)01248-7.
15. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. International journal of nephrology and renovascular disease. 2008 Dec;1:19. DOI: 10.2147/ijnrd.s3108.
16. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018 Nov 13;138(20):2132-46. DOI: 10.1161/CIRCULATIONAHA.